<html>
<head>
<title></title>
<!--Licensed to: Willkie Farr & Gallagher LLP
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">As filed with the Securities and Exchange Commission on August&#160;3, 2016</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt">Registration No. 333-</div>

<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11pt"><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">UNITED STATES</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Washington, D.C. 20549</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11pt"><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif">FORM S-8</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif">REGISTRATION STATEMENT</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> UNDER THE SECURITIES ACT OF 1933</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 8pt"><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Exact name of registrant as specified in its charter)</div>

<table id="22e092fe5f1145e289127a1d4b432af3" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 9.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Israel</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>(State or other jurisdiction<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> or incorporation or organization)</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 9.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Not Applicable</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>(I.R.S. Employer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Identification Number)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 9.1pt">5 Basel Street<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>P.O. Box 3190<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Petach Tikva, 4951033 Israel<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>(Address of Principal Executive Offices)<br style="LINE-HEIGHT: 6.85pt">
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11pt">
<hr style="HEIGHT: 2px; WIDTH: 20%; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
<font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Teva Pharmaceutical Industries Limited</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">2015 Long-Term Equity-Based Incentive Plan</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Full title of the plan)</div>

<div style="MARGIN-BOTTOM: 3pt; LINE-HEIGHT: 6.85pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 9.1pt">
<hr style="HEIGHT: 2px; WIDTH: 20%; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Teva Pharmaceuticals USA, Inc.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1090 Horsham Road</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">North Wales, Pennsylvania 19454</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Attention:&#160; Deborah Griffin</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(215) 591-3000</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Name, address and telephone number, including area code, of agent for service)</div>

<div style="MARGIN-BOTTOM: 3pt; LINE-HEIGHT: 6.85pt"><br style="LINE-HEIGHT: 6.85pt">
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">
<hr style="HEIGHT: 2px; WIDTH: 20%; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
Copy to:<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Jeffrey&#160;S. Hochman, Esq.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Michael&#160;A. Katz, Esq.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Willkie Farr &amp; Gallagher LLP<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>787 Seventh Avenue<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>New York, New York 10019-6099<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (212) 728-8000</div>

<div style="MARGIN-BOTTOM: 6pt; LINE-HEIGHT: 6.85pt"><br style="LINE-HEIGHT: 6.85pt">
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 9.1pt">
<hr style="HEIGHT: 2px; WIDTH: 20%; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.&#160; See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule 12b-2 of the Exchange Act.&#160; (Check one):</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: center; LINE-HEIGHT: 9.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Large accelerated filer</font>&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Accelerated filer &#9744;</font></div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 9.1pt">Non-accelerated filer &#9744;&#160;(Do not check if a smaller reporting company)&#160;&#160; Smaller reporting company &#9744;</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 6pt; LINE-HEIGHT: 11.4pt">CALCULATION OF REGISTRATION FEE</div>

<table id="f1cab6f68efa42859d4ecd860731d1d7" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP: #000000 4px double; BORDER-RIGHT: #000000 2px solid; WIDTH: 27.33%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Title of securities to be registered&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 4px double; BORDER-RIGHT: #000000 2px solid; WIDTH: 17.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Amount to be registered&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 4px double; BORDER-RIGHT: #000000 2px solid; WIDTH: 17.92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Proposed maximum offering price per share&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 4px double; BORDER-RIGHT: #000000 2px solid; WIDTH: 16.83%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Proposed maximum aggregate offering price</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 4px double; WIDTH: 20%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Amount of registration fee</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid; WIDTH: 27.33%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 4px double">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Ordinary Shares, NIS 0.1 par value,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> deposited as American Depositary Shares</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid; WIDTH: 17.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">35,300,000</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid; WIDTH: 17.92%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">$53.24</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid; WIDTH: 16.83%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">$1,879,372,000.00</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; WIDTH: 20%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">$189,252.76</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 8pt">
<table id="f4eb168bce214f999b89fb45eee6bbe0" class="DSPFListTable" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">American Depositary Shares (&#8220;ADSs&#8221;) issuable on deposit of ordinary shares of Teva Pharmaceutical Industries Limited (the&#160;&#8220;Registrant&#8221;), NIS&#160;0.1 par value (&#8220;ordinary shares&#8221;), have been registered under a separate registration statement.&#160; One ADS equals one Ordinary Share.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: left; LINE-HEIGHT: 8pt">
<table id="99d32ae62db84451a2410b6765f1243a" class="DSPFListTable" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">This Registration Statement on Form&#160;S-8 (this&#160;&#8220;Registration Statement&#8221;) covers 35,300,000 additional ordinary shares which may be issued under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (the&#160;&#8220;Plan&#8221;), including (i)&#160;33,300,000 ordinary shares which were approved by the Registrant&#8217;s shareholders at its Annual Meeting of Shareholders on April&#160;18, 2016 and (ii)&#160;2,000,000 ordinary shares subject to share options, restricted shares and restricted share units issued under the Plan as &#8220;substitute awards&#8221; in connection with the consummation of the Registrant&#8217;s acquisition of the global generics business of Allergan plc (&#8220;Allergan&#8221;) pursuant to that certain Master Purchase Agreement, dated as of July&#160;26, 2015, as amended, by and between the Registrant and Allergan.&#160; These &#8220;substitute awards&#8221; were granted under the Plan in exchange for share options, restricted shares and restricted share units granted to employees of Allergan prior to the transaction under the Allergan stock incentive plans.&#160; In addition, this Registration Statement covers an indeterminable number of additional ordinary shares as may hereafter be offered or issued pursuant to the Plan to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration and pursuant to Rule 416 under the Securities Act of 1933, as amended (the&#160;&#8220;Securities Act&#8221;).</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: left; LINE-HEIGHT: 8pt">
<table id="e3f76be663714d53b40241d09b5886f6" class="DSPFListTable" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 24px; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">Estimated solely for calculating the amount of the registration fee, pursuant to Rules&#160;457(c) and 457(h) under the Securities Act, based upon the average of the high and low prices per share of the ordinary shares represented by ADSs on August 2, 2016, as reported by The New York Stock Exchange.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br style="LINE-HEIGHT: 8pt">
</div>

<div style="LINE-HEIGHT: 1.15pt"><br style="LINE-HEIGHT: 1.15pt">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 12pt; CLEAR: both; MARGIN-TOP: 12pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal"></font>&#160;</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">EXPLANATORY NOTE</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">On September&#160;9, 2015, Teva Pharmaceutical Industries Limited (the&#160;&#8220;Registrant&#8221;) filed a Registration Statement on Form S-8 (File No. 333-206753) (the&#160;&#8220;Prior Registration Statement&#8221;) to register 46,200,000 ordinary shares of the Registrant, NIS&#160;0.1 par value (&#8220;ordinary shares&#8221;), which may be issued under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (the&#160;&#8220;Plan&#8221;).</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">On April&#160;18, 2016, at the Registrant&#8217;s Annual Meeting of Shareholders, the Registrant&#8217;s shareholders approved an amendment to the Plan to increase the number of ordinary shares available for issuance thereunder by an additional 33,300,000 shares.</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">In connection with the consummation of the Registrant&#8217;s acquisition of the global generics business of Allergan plc (&#8220;Allergan&#8221;) pursuant to that certain Master Purchase Agreement, dated as of July&#160;26, 2015, as amended, by and between the Registrant and Allergan, the Registrant issued &#8220;substitute awards&#8221; of share options, restricted shares and restricted share units under the Plan.&#160; These &#8220;substitute awards&#8221; were granted under the Plan in exchange for share options, restricted shares and restricted share units granted to employees of Allergan prior to the transaction under the Allergan stock incentive plans.&#160; The ordinary shares subject to the &#8220;substitute awards&#8221; were issued in reliance on the &#8220;mergers and acquisitions&#8221; exemption to the shareholder approval requirements under Section&#160;303A.08 of The New York Stock Exchange Listed Company Manual.</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">Pursuant to General Instruction&#160;E of Form&#160;S-8, this Registration Statement on Form&#160;S-8 (this&#160;&#8220;Registration Statement&#8221;) is filed by the Registrant to register 35,300,000 additional ordinary shares, including (i)&#160;33,300,000 ordinary shares which were approved by the Registrant&#8217;s shareholders at its Annual Meeting of Shareholders on April&#160;18, 2016 and (ii)&#160;2,000,000 ordinary shares subject to the &#8220;substitute awards&#8221; issued under the Plan to former employees of Allergan.&#160; In accordance with General Instruction&#160;E of Form&#160;S-8, the contents of the Prior Registration Statement are incorporated herein by reference, including all exhibits filed therewith or incorporated therein by reference, except as supplemented, amended or superseded by the information set forth below.</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">PART II</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">INFORMATION REQUIRED IN THE<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> REGISTRATION STATEMENT</div>

<div style="MARGIN-BOTTOM: 10pt; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">
<table id="bafd1b76c98c49348ceecfd93ad0ea7c" class="DSPFListTable" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 45pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 8.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: left">EXHIBITS</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">The exhibits to this Registration Statement are listed in the Exhibit Index and incorporated herein by reference.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 12pt; CLEAR: both; MARGIN-TOP: 12pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal"></font>&#160;</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">SIGNATURES</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#160;S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Petach Tikva, State of Israel, on the 3rd day of August, 2016.</div>

<table id="f9dcb92cc2b741bdae23a1a4a2e71571" style="FONT-SIZE: 12pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 47.03%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 52.97%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" colspan="2">
<div style="MARGIN-BOTTOM: 24pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 47.03%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 3.17%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; FONT-VARIANT: normal; WIDTH: 49.52%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; FONT-WEIGHT: normal; FONT-STYLE: normal; BORDER-LEFT: medium none">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><u>/s/ Erez Vigodman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 47.03%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 3.17%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 49.52%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Erez Vigodman</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 47.03%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 3.17%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 49.52%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">President and</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Chief Executive Officer</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 47.03%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 3.17%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 49.52%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">POWER OF ATTORNEY</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned directors and/or officers of the Registrant hereby constitutes and appoints Erez Vigodman, Eyal Desheh, Richard&#160;S. Egosi and Deborah Griffin, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and deliver with the Commission under the Securities Act any and all post-effective amendments to this Registration Statement and generally to do all things and perform any and all acts and things whatsoever requisite and necessary or desirable to enable the Registrant to comply with the provisions of the Securities Act and all requirements of the Commission.</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">[<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Signatures appear on the following page.</font>]</div>

<div style="MARGIN-BOTTOM: 10pt; LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 12pt; CLEAR: both; MARGIN-TOP: 12pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:</div>

<table id="10aaa72c55014983834fcfa8d6a5e794" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 34.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 2px solid; FONT-WEIGHT: normal; FONT-STYLE: normal" colspan="2">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><u>Name</u></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 34.26%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 2px solid; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><u>Title</u></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 31.29%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 2px solid; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><u>Date</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>

<div style="LINE-HEIGHT: 11.4pt">&#160;</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="LINE-HEIGHT: 11.4pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Prof. Yitzhak Peterburg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Prof.&#160;Yitzhak Peterburg</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Chairman of the Board</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>

<div style="LINE-HEIGHT: 11.4pt">&#160;</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Erez Vigodman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Erez Vigodman</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">President, Chief Executive Officer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>and Director<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Principal Executive Officer)</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>

<div style="LINE-HEIGHT: 11.4pt">&#160;</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Eval Desheh&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Eyal Desheh</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Group Executive Vice President<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>and Chief Financial Officer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Principal Financial Officer)</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>

<div style="LINE-HEIGHT: 11.4pt">&#160;</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Deborah Griffin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Deborah Griffin</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Senior Vice President and<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Chief Accounting Officer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Principal Accounting Officer)</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/&#160;Roger Abravanel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Roger Abravanel</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; WIDTH: 5.27%; VERTICAL-ALIGN: top">By:&#160;</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal">Sol J. Barer</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div>&#160;</div>

<div style="FONT-SIZE: 10pt">Director&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; WIDTH: 5.27%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 12pt; WIDTH: 29.18%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="FONT-SIZE: 12pt; WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 12pt; WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; WIDTH: 5.27%; VERTICAL-ALIGN: top">By:&#160;</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>

<div style="FONT-SIZE: 10pt">Arie Belldegrun&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div>&#160;</div>

<div>Director&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; WIDTH: 5.27%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 12pt; WIDTH: 29.18%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="FONT-SIZE: 12pt; WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 12pt; WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; WIDTH: 5.27%; VERTICAL-ALIGN: top">By:&#160;</td>
<td style="FONT-SIZE: 10pt; WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal">Rosemary A. Crane&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div>&#160;</div>

<div>Director&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Amir Elstein&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Amir Elstein</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Jean-Michel Halfon&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Jean-Michel Halfon</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Gerald M. Lieberman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Gerald&#160;M. Lieberman</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Galia Maor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Galia Maor</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Joseph Nitzani&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Joseph Nitzani</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Ory Slonim&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Ory Slonim</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Director</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.45%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="FONT-SIZE: 10pt; WIDTH: 5.27%; VERTICAL-ALIGN: top">By:&#160;</td>
<td style="FONT-SIZE: 10pt; WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Gabrielle Sulzberger&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></div>

<div>Gabrielle Sulzberger&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div>&#160;</div>

<div>Director&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; WIDTH: 31.29%; VERTICAL-ALIGN: bottom">August 3, 2016</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>/s/ Deborah Griffin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Deborah Griffin</div>
</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Authorized U.S. Representative</div>
</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">August&#160;3, 2016</div>
</td>
</tr>

<tr>
<td style="WIDTH: 5.27%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 29.18%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 34.26%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.29%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 12pt; LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 12pt; CLEAR: both; MARGIN-TOP: 12pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">EXHIBIT INDEX</div>

<table id="09a0b45f9d8f4b989750c3113c2420c0" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" rowspan="2">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Exhibit<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> No.</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" rowspan="2">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Description</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 41%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="4">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Incorporated by Reference</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" rowspan="2">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt">Filed<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Herewith</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 36pt; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt; TEXT-INDENT: -36pt">Form</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 36pt; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt; TEXT-INDENT: -36pt">File No.</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 36pt; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt; TEXT-INDENT: -36pt">Exhibit</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="LINE-HEIGHT: 14.4pt">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 36pt; MARGIN-TOP: 3pt; LINE-HEIGHT: 9.1pt; TEXT-INDENT: -36pt">Filing Date</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">4.1</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Amended and Restated Deposit Agreement, dated November&#160;5, 2012, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank, N.A., as depositary, and the owners and holders from time to time of American Depositary Shares issued thereunder, including the form of American Depositary Receipt contained therein</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">F-6</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">333-<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">184652</font></div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">99.(a)</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">October&#160;30, 2012</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">4.2</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Amendment to Deposit Agreement, dated February&#160;29, 2016, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank, N.A., as depositary, and the owners and holders from time to time of American Depositary Shares issued thereunder, including the form of American Depositary Receipt contained therein</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">F-6 POS</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">333-<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">208239</font></div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">99.(a)(2)</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">February&#160;29, 2016</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">5.1</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Opinion of Tulchinsky Stern Marciano Cohen Levitski &amp;&#160;Co.</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">5.2</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Opinion of Willkie Farr &amp; Gallagher LLP</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">23.1</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Consent of Kesselman &amp; Kesselman &#8211; Independent Registered Public Accounting Firm to the Registrant</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">23.2</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Consent of PricewaterhouseCoopers LLP &#8211; Independent Registered Public Accounting Firm to Allergan</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">23.3</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Consent of Tulchinsky Stern Marciano Cohen Levitski &amp;&#160;Co. (included in Exhibit&#160;5.1)</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">23.4</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Consent of Willkie Farr &amp; Gallagher LLP (included in Exhibit&#160;5.2)</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">24.1</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Power of Attorney (included on signature page of this Registration Statement)</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">X</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 6.82%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">99.1</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 46.06%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">6-K</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 9.56%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">001-16174</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 7.82%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">Ex.&#160;B</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 16.3%; VERTICAL-ALIGN: middle">
<div style="LINE-HEIGHT: 0pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt; LINE-HEIGHT: 11.4pt">July&#160;30, 2015</div>

<div style="LINE-HEIGHT: 0pt">&#160;</div>
</td>
<td style="WIDTH: 6.12%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 12pt; LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>
</div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "t15696974a.htm", "description": "FORM S-8 REGISTRATION STATEMENT", "secsgml_size_bytes": 75725}]
{"company-data": {"conformed-name": "TEVA PHARMACEUTICAL INDUSTRIES LTD", "cik": "0000818686", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "L3", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-212851", "film-number": "161802410"}, "business-address": {"street1": "5 BAZEL ST", "street2": "P O B 3190", "city": "PETACH TIKVA", "state": "L3", "zip": "49131", "phone": "9729267267"}, "mail-address": {"street1": "TEVA PHARMACEUTICAL INDUSTRIES LIMITED", "street2": "5 BAZEL ST PO B 3190", "city": "PETACH TIKVA", "state": "L3", "zip": "49131"}}
As filed with the Securities and Exchange Commission on August 3, 2016
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
Israel
(State or other jurisdiction
or incorporation or organization)
Not Applicable
(I.R.S. Employer
Identification Number)
5 Basel Street
P.O. Box 3190
Petach Tikva, 4951033 Israel
(Address of Principal Executive Offices)
Teva Pharmaceutical Industries Limited
2015 Long-Term Equity-Based Incentive Plan
(Full title of the plan)
Teva Pharmaceuticals USA, Inc.
1090 Horsham Road
North Wales, Pennsylvania 19454
Attention:  Deborah Griffin
(215) 591-3000
(Name, address and telephone number, including area code, of agent for service)
Copy to:
Jeffrey S. Hochman, Esq.
Michael A. Katz, Esq.
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019-6099
(212) 728-8000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.  See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer
☒
Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting company)   Smaller reporting company ☐
CALCULATION OF REGISTRATION FEE
Title of securities to be registered
(1)
Amount to be registered
(2)
Proposed maximum offering price per share
(3)
Proposed maximum aggregate offering price
Amount of registration fee
Ordinary Shares, NIS 0.1 par value,
deposited as American Depositary Shares
35,300,000
$53.24
$1,879,372,000.00
$189,252.76
(1)
American Depositary Shares ("ADSs") issuable on deposit of ordinary shares of Teva Pharmaceutical Industries Limited (the "Registrant"), NIS 0.1 par value ("ordinary shares"), have been registered under a separate registration statement.  One ADS equals one Ordinary Share.
(2)
This Registration Statement on Form S-8 (this "Registration Statement") covers 35,300,000 additional ordinary shares which may be issued under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (the "Plan"), including (i) 33,300,000 ordinary shares which were approved by the Registrant's shareholders at its Annual Meeting of Shareholders on April 18, 2016 and (ii) 2,000,000 ordinary shares subject to share options, restricted shares and restricted share units issued under the Plan as "substitute awards" in connection with the consummation of the Registrant's acquisition of the global generics business of Allergan plc ("Allergan") pursuant to that certain Master Purchase Agreement, dated as of July 26, 2015, as amended, by and between the Registrant and Allergan.  These "substitute awards" were granted under the Plan in exchange for share options, restricted shares and restricted share units granted to employees of Allergan prior to the transaction under the Allergan stock incentive plans.  In addition, this Registration Statement covers an indeterminable number of additional ordinary shares as may hereafter be offered or issued pursuant to the Plan to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration and pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act").
(3)
Estimated solely for calculating the amount of the registration fee, pursuant to Rules 457(c) and 457(h) under the Securities Act, based upon the average of the high and low prices per share of the ordinary shares represented by ADSs on August 2, 2016, as reported by The New York Stock Exchange.
EXPLANATORY NOTE
On September 9, 2015, Teva Pharmaceutical Industries Limited (the "Registrant") filed a Registration Statement on Form S-8 (File No. 333-206753) (the "Prior Registration Statement") to register 46,200,000 ordinary shares of the Registrant, NIS 0.1 par value ("ordinary shares"), which may be issued under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (the "Plan").
On April 18, 2016, at the Registrant's Annual Meeting of Shareholders, the Registrant's shareholders approved an amendment to the Plan to increase the number of ordinary shares available for issuance thereunder by an additional 33,300,000 shares.
In connection with the consummation of the Registrant's acquisition of the global generics business of Allergan plc ("Allergan") pursuant to that certain Master Purchase Agreement, dated as of July 26, 2015, as amended, by and between the Registrant and Allergan, the Registrant issued "substitute awards" of share options, restricted shares and restricted share units under the Plan.  These "substitute awards" were granted under the Plan in exchange for share options, restricted shares and restricted share units granted to employees of Allergan prior to the transaction under the Allergan stock incentive plans.  The ordinary shares subject to the "substitute awards" were issued in reliance on the "mergers and acquisitions" exemption to the shareholder approval requirements under Section 303A.08 of The New York Stock Exchange Listed Company Manual.
Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 (this "Registration Statement") is filed by the Registrant to register 35,300,000 additional ordinary shares, including (i) 33,300,000 ordinary shares which were approved by the Registrant's shareholders at its Annual Meeting of Shareholders on April 18, 2016 and (ii) 2,000,000 ordinary shares subject to the "substitute awards" issued under the Plan to former employees of Allergan.  In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference, including all exhibits filed therewith or incorporated therein by reference, except as supplemented, amended or superseded by the information set forth below.
PART II
INFORMATION REQUIRED IN THE
REGISTRATION STATEMENT
Item 8.
EXHIBITS
The exhibits to this Registration Statement are listed in the Exhibit Index and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Petach Tikva, State of Israel, on the 3rd day of August, 2016.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
By:
/s/ Erez Vigodman
Erez Vigodman
President and
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned directors and/or officers of the Registrant hereby constitutes and appoints Erez Vigodman, Eyal Desheh, Richard S. Egosi and Deborah Griffin, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and deliver with the Commission under the Securities Act any and all post-effective amendments to this Registration Statement and generally to do all things and perform any and all acts and things whatsoever requisite and necessary or desirable to enable the Registrant to comply with the provisions of the Securities Act and all requirements of the Commission.
[
Signatures appear on the following page.
]
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Name
Title
Date
By:
/s/ Prof. Yitzhak Peterburg
Prof. Yitzhak Peterburg
Chairman of the Board
August 3, 2016
By:
/s/ Erez Vigodman
Erez Vigodman
President, Chief Executive Officer
and Director
(Principal Executive Officer)
August 3, 2016
By:
/s/ Eval Desheh
Eyal Desheh
Group Executive Vice President
and Chief Financial Officer
(Principal Financial Officer)
August 3, 2016
By:
/s/ Deborah Griffin
Deborah Griffin
Senior Vice President and
Chief Accounting Officer
(Principal Accounting Officer)
August 3, 2016
By:
/s/ Roger Abravanel
Roger Abravanel
Director
August 3, 2016
By:
Sol J. Barer
Director
By:
Arie Belldegrun
Director
By:
Rosemary A. Crane
Director
By:
/s/ Amir Elstein
Amir Elstein
Director
August 3, 2016
By:
/s/ Jean-Michel Halfon
Jean-Michel Halfon
Director
August 3, 2016
By:
/s/ Gerald M. Lieberman
Gerald M. Lieberman
Director
August 3, 2016
By:
/s/ Galia Maor
Galia Maor
Director
August 3, 2016
By:
/s/ Joseph Nitzani
Joseph Nitzani
Director
August 3, 2016
By:
/s/ Ory Slonim
Ory Slonim
Director
August 3, 2016
By:
/s/ Gabrielle Sulzberger
Gabrielle Sulzberger
Director
August 3, 2016
By:
/s/ Deborah Griffin
Deborah Griffin
Authorized U.S. Representative
August 3, 2016
EXHIBIT INDEX
Exhibit
No.
Description
Incorporated by Reference
Filed
Herewith
Form
File No.
Exhibit
Filing Date
4.1
Amended and Restated Deposit Agreement, dated November 5, 2012, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank, N.A., as depositary, and the owners and holders from time to time of American Depositary Shares issued thereunder, including the form of American Depositary Receipt contained therein
F-6
333-
184652
99.(a)
October 30, 2012
4.2
Amendment to Deposit Agreement, dated February 29, 2016, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank, N.A., as depositary, and the owners and holders from time to time of American Depositary Shares issued thereunder, including the form of American Depositary Receipt contained therein
F-6 POS
333-
208239
99.(a)(2)
February 29, 2016
5.1
Opinion of Tulchinsky Stern Marciano Cohen Levitski & Co.
X
5.2
Opinion of Willkie Farr & Gallagher LLP
X
23.1
Consent of Kesselman & Kesselman – Independent Registered Public Accounting Firm to the Registrant
X
23.2
Consent of PricewaterhouseCoopers LLP – Independent Registered Public Accounting Firm to Allergan
X
23.3
Consent of Tulchinsky Stern Marciano Cohen Levitski & Co. (included in Exhibit 5.1)
X
23.4
Consent of Willkie Farr & Gallagher LLP (included in Exhibit 5.2)
X
24.1
Power of Attorney (included on signature page of this Registration Statement)
X
99.1
Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan
6-K
001-16174
Ex. B
July 30, 2015